Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000273 · ClinicalTrials.gov registry record · Phase 2
A Laboratory Model for Heroin Abuse Medications - 8
A Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT00000273 is a Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00000273, a Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
Conditions Studied
Interventions
- DRUG opiates
Study Locations (2)
New York
- Columbia University - New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 1995-08 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000273
The ClinicalTrials.gov registry entry for NCT00000273 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (99% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which opiates is the first listed.
NCT00000273 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00000273 about?
NCT00000273 is a clinical study titled "A Laboratory Model for Heroin Abuse Medications - 8". The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
What is the current status of trial NCT00000273?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 1995-08. Estimated completion is 2005-11.
What conditions does trial NCT00000273 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Opioid-Related Disorders, Heroin Dependence.
What interventions are being tested in trial NCT00000273?
The interventions under investigation include: opiates (DRUG).
Who is sponsoring clinical trial NCT00000273?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000273 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
RECRUITING · Phase 2
-
GLP-1R Agonist Treatment for Opioid Use Disorder
RECRUITING · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
-
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
COMPLETED · Phase 2
-
Buprenorphine Maintenance for Opiate Dependence - 6
COMPLETED · Phase 2
-
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.